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Bipolar Disorder: A Pharmacotherapy Management Overview
by Huong Le, Pharm.D. Candidate 2014, Julie Nguyen, Pharm.D. Candidate 2014, Tina Pham, Pharm.D. Candidate 2014, Laura Tsu, 
Pharm.D., BCPS, Midwestern University College of Pharmacy – Glendale 
Goals
This home-study CPE activity has been 
developed to educate pharmacists on 
bipolar disorder and its management using 
non-pharmacologic and pharmacologic 
therapies.
Objectives
1. Distinguish between Bipolar Disorder 
I and Bipolar Disorder II and the 
different mood disorders 
2. Compare the differences between a 
manic and a depressive state
3. Develop a therapeutic plan for a 
newly diagnosed bipolar patient 
4. Compare different pharmacologic 
agents in terms of efficacy, adverse 
effects, and monitoring
5. Design treatment recommendations 
for special population groups
Introduction
Bipolar disorder is a common and 
debilitating mood disorder, with an 
estimated lifetime prevalence of bipolar 
I disorder and bipolar II disorder of 1% 
and 1.1%, respectively, in the United 
States.1  The mean age of onset for bipolar 
I disorder and bipolar II disorder is 18 and 
20 years, respectively, with equal gender 
prevalence occurring in bipolar I disorder 
and a higher prevalence in women for 
bipolar II disorder.1  The pathophysiology 
of bipolar disorder is unknown, but the 
etiology is thought to involve biological, 
psychological, and social factors.  There 
is a complex genetic component with 
80-90% of patients with bipolar disorder 
having a relative with a mood disorder.  
The brain structure and function in these 
patients are also altered, but it is unclear 
if these changes occurred before or after 
clinical presentation of the disorder.1 
Environmental influences such as stressful 
life events, alcohol or substance abuse, 
and changes in sleep-wake cycle may 
also affect the course of the disorder 
by dysregulating neurotransmitters, 
hormones, endocrine function, 
neuropeptides, cations, intracellular 
messengers, and signal transduction 
pathways.  Appropriately diagnosing 
bipolar disorder is crucial, because there 
are other psychiatric and neurologic 
disorders that may present similarly with 
manic-like or depressive-like symptoms.1 
For example, if an individual with bipolar 
disorder was misdiagnosed to have 
attention-deficit/hyperactivity disorder 
(ADHD), the central nervous system 
stimulant prescribed can actually worsen 
symptoms of mania or depression and 
decrease response to treatment.  There are 
three types of bipolar disorder.  Bipolar I 
Disorder primarily presents with manic, 
or rapid cycling episodes of mania and 
depression.  Bipolar II Disorder primarily 
presents with recurrent depression 
accompanied by hypomanic episodes.  
Cyclothymic Disorder is a chronic state 
of cycling between hypomanic and 
dysthymic episodes that do not reach the 
diagnostic criteria for bipolar disorder.1 
Diagnosis
Major Depressive
Depressed mood and/or loss of interest or 
pleasure for at least 2 weeks and at least 5 
of the following:2 
1. Depressed mood
2. Decreased interest or pleasure in 
normal activities 
3. Unintentional weight loss or gain
4. Insomnia or hypersomnia 
5. Agitation or psychomotor retardation 
6. Fatigue or decreased energy 
7. Feelings of worthlessness or guilt 
8. Decreased ability to concentrate or 
make decisions 
9. Suicidal thoughts
Dysthymic Disorder 
Depressed mood for more days than not 
for at least 2 years and at least 2 of the 
following:2
1. Loss of appetite or overeating 
2. Insomnia or hypersomnia 
3. Fatigue or decreased energy
4. Low self-esteem 
5. Decreased ability to concentrate or 
make decisions
6. Feelings of hopelessness 
Manic
Abnormal and persistent elevated mood 
for at least 1 week and at least 3 of the 
following:2
1. Inflated self-esteem or grandiosity 
2. Decreased need for sleep
3. Increased talking
4. Flight of ideas or racing thoughts 
5. Distractible 
6. Increased  activity (socially, at work, 
or sexually) 
7. Increased psychomotor agitation 
8. Excessive involvement in pleasurable 
activities that have high risk for 
serious consequences 
Hypomanic
Abnormal and persistent elevated mood 
for at least 4 days and at least 3 of the 
following:2 
1. Inflated self-esteem or grandiosity
2. Decreased need for sleep
3. Increased talking
4. Increased  activity (socially, at work, 
or sexually) 
5. Increased psychomotor agitation 
6. Excessive involvement in pleasurable 
activities that have high risk for 
serious consequences 
Mixed
Criteria for both major depressive and 
manic episodes that occur almost every 
day for at least a 1 week period.2 
Rapid cycling 
More than 4 major depressive or manic 
episodes (manic, hypomanic, or mixed) in 
12 months.2
Non-Pharmacological Treatments 
The goals of treatment for bipolar 
disorders aim to achieve remission, 
which is defined as complete return 
to normal functioning and lack of 
symptoms, to prevent relapses, to control 
comorbid conditions including anxiety, 
panic disorder, obsessive-compulsive 
disorder (OCD), and ADHD.  Three 
non-pharmacological approaches to the 
treatment of bipolar disorders encompass 
health maintenance, mood charting, and 
a combination of pharmacotherapy plus 
psychoeducation.3  Maintaining health 
through adequate sleep, nutrition, and 
exercise can improve and prevent signs 
and symptoms of bipolar episodes.  
Benzodiazepines, melatonin, enforced 
darkness, and prolonged bed rest have 
been shown to help patients sleep.  Sleep 
hygiene is also crucial in obtaining 
adequate sleep.  This includes counseling 
patients to establish a fixed sleep and 
wake time, to exercise but not close to 
bedtime, and to avoid naps.  In addition 
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to getting adequate sleep, nutrition plays 
an important role in managing bipolar 
disorders.  Patients should be counseled to 
maintain an adequate intake of essential 
amino acids, fatty acids, vitamins, and 
minerals based on the Reference Daily 
Intake (RDI).3  Exercise, either strength 
training or aerobic, can help with sleep 
and major depressive disorder (MDD) by 
increasing the synthesis and release of 
neurotransmitters such as serotonin and 
norepinephrine.4  Mood charting is another 
approach to manage bipolar disorders by 
assisting patients in detecting signs and 
symptoms of episodes and assessing their 
responsiveness and tolerability to the 
drug regimen.  Finally, a combination of 
pharmacotherapy and psychoeducation 
can enhance the treatments and prevent 
relapses of bipolar episodes.  Cognitive 
behavior therapy, reducing psychosocial 
stressors, mental health organizations, and 
other support groups, including individual 
or family therapy, are recommended as 
adjunct therapies to pharmacologic agents. 
Other non-pharmacologic approaches 
have been shown to be effective in 
treating patients who have failed 
pharmacologic agents.  These approaches 
include electroconvulsive therapy (ECT), 
transcranial magnetic stimulation, and 
vagus nerve stimulation.  
Pharmacological Treatments
Manic Phase (Acute Manic, Hypomanic, 
Mixed)
The manic phase can be acute manic, 
hypomanic, or mixed.  The treatment plans 
in the manic phase include remission, 
assessment of the causes and triggers 
such as alcohol, drug, or substance 
abuse.  Other contributory factors can be 
stimulants, caffeine, or antidepressant 
monotherapy.  For severe cases of mania, 
first line treatments are combinations of 
lithium plus antipsychotics or valproate 
plus antipsychotics.5,6  For less severe 
cases, lithium, valproate, or antipsychotic 
monotherapy is sufficient.  Alternatives to 
lithium or valproate can be carbamazepine 
or oxcarbazepine.  Adjunctive therapy 
with psychosocial approaches can also be 
beneficial.  For mixed or rapid cycling, 
valproate is preferred over lithium.  
Whenever psychosis is manifested in 
the manic phase, antipsychotics need 
to be considered.5,6  Second generation 
antipsychotics (SGAs), also known as 
atypical antipsychotics are preferred 
over first generation antipsychotics 
(FGAs), also known as typical 
antipsychotics.  SGAs have lower risk of 
extrapyramidal side effects such as tardive 
dyskinesia, dystonia, and Parkinson’s 
like symptoms and have less effects 
on prolactin.5,6  Examples of SGAs are 
olanzapine, ziprasidone, risperidone, 
and quetiapine.  Examples of FGAs 
are chlorpromazine, fluphenazine, and 
haloperidol.  For breakthrough manic 
or mixed episodes, the dose should be 
optimized to the therapeutic range, add 
or continue antipsychotics, or consider 
adding a short-term benzodiazepine.  If 
patients are refractory to the first line 
treatments, the recommendations are to 
add another first line agent, carbamazepine 
or oxcarbazepine, add or switch an 
antipsychotic, or utilize ECT.5,6 
Depressive Phase
The treatment plans for the depressive 
phase aim to achieve remission, avoid 
antidepressant monotherapy due to 
precipitation of mania or hypomania, 
assess causes or triggers of depression 
such as alcohol, drug or substance 
abuse, and to taper off antipsychotics, 
benzodiazepines, and sedative-hypnotics.  
First line agents for bipolar depression 
are lithium or lamotrigine.  Alternative 
agents are quetiapine monotherapy or 
olanzapine plus fluoxetine, valproate, 
lithium plus antidepressant, or adjunctive 
psychotherapy.5,6  In July 2013, lurasidone 
was approved as monotherapy or 
adjunctive therapy in the treatment of 
bipolar depression.  For breakthrough 
bipolar depression, optimize dose of 
the maintenance drug until it is within 
therapeutic range.7  For patients who are 
refractory to first line treatments, add 
lamotrigine, bupropion, paroxetine or 
alternatively add other antidepressants or 
monoamine oxidase inhibitors (MAOIs).  
ECT is recommended for severe, 
refractory depression with psychosis or 
catatonia.5,6 
Rapid Cycling
The treatment plans for rapid cycling 
are to reduce the numbers of episode 
and assess issues that can contribute to 
cycling, including hypothyroidism, drug or 
substance abuse, or alcoholism.  First line 
agents include lithium or valproate, and an 
alternative would be lamotrigine.  Rapid-
cycling patients will eventually require 
combination therapy.5,6 
Maintenance Treatments
Following an episode, all patients 
are required to be on maintenance 
or continuation of therapy for up to 
six months due to the high risk of 
relapse.  The selection of medications 
for maintenance agents is the agent 
that induces remission.  Furthermore, 
psychosocial therapies such as evaluating 
adherence, support groups, lifestyle, 
and mood charting are also considered.  
First line agents for maintenance are 
lithium or valproate with lamotrigine, 
carbamazepine, or oxcarbazepine as 
alternatives.  Antipsychotics should be 
evaluated for risks versus benefits before 
considering them for long-term use.  In 
bipolar I, the duration of maintenance 
after one manic episode is 12 months, and 
lifelong for more than one episode.  In 
bipolar II, the duration of maintenance 
after one to two hypomanic phases is 12 
months, and lifelong if more than two 
episodes.5,6 
Drug Therapies 
Lithium (Eskalith®, Lithobid®)
Lithium works by affecting the reuptake 
of serotonin and norepinephrine.  In 
doing so, lithium can be used for the 
depressive stage of bipolar.  However, 
lithium has a stronger effect on managing 
mania by suppressing excitatory 
neurotransmission (e.g. dopamine and 
glutamate) while increasing inhibitory 
activity (GABA).7  Studies have shown 
that lithium has similar efficacy to 
valproate, carbamazepine, risperidone, 
olanzapine, chlorpromazine and other first 
generation antipsychotics.  Its efficacy is 
enhanced in patients who have fewer prior 
episodes, family history of responsiveness 
to lithium, and euthymia between 
episodes.  In mixed or rapid-cycling, the 
efficacy of lithium is reduced.  Lithium 
is used as a first line agent for mania, 
hypomania, depression, and maintenance.  
Combination therapy with carbamazepine, 
valproate, and antipsychotics can be seen.  
Adverse effects are seen in multiple 
organs and can be dose dependent.  
Central nervous system (CNS) effects 
of headache, memory and cognitive 
impairments, coma, confusion, seizure, 
sedation, lethargy and stupor are dose 
related.  Other dose related side effects 
include nausea, vomiting, diarrhea, 
dyspepsia, weight gain, hair loss, 
worsening of rash or psoriasis, and 
tremor.  Lithium can decrease response 
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to antidiuretic hormones (ADH), causing 
polyuria, polydipsia, and nocturia.  Other 
dose related effects on the kidneys include 
albuminuria and glycosuria.  Lithium 
can accumulate in the thyroid gland 
and interfere with synthesis of thyroid 
hormones, thus causing hypothyroidism.  
Lithium can also cause cardiac problems 
such as atrioventricular (AV) block, 
arrhythmias, hypotension, syncope and 
ECG changes.  Thus, patients with a 
history of cardiac abnormalities need to 
have their ECG monitored at baseline and 
during treatment.  Lithium can further lead 
to leukocytosis and blurred vision.  Unlike 
other pharmacologic treatments for bipolar 
disorder, the long term use of lithium can 
reduce risk of suicidal ideation.
Drugs that can increase lithium 
concentration include ACE inhibitors, 
NSAIDs, and thiazides while theophylline, 
caffeine, and loop diuretics can decrease 
lithium concentration.  Dehydration, 
vomiting, or diarrhea can also raise 
lithium levels.  At the initiation of therapy, 
serum levels are drawn twice weekly until 
the level is stabilized.  Once stabilized, 
it is then recommended to draw levels 
every 2 months.  Serum concentrations 
for acute episodes are 1 – 1.2 mEq/L 
and 0.6 – 1.2 mEq/L for maintenance.  
Furthermore, electrolytes, thyroid function 
tests, hematologic and dermatologic 
tests should be monitored at baseline and 
every 6-12 months, with the exception of 
dermatologic test, which should be done 
every 3-6 months.
Monitoring serum levels of lithium is 
important to avoid toxicity, which can be 
seen when the serum level is greater than 
1.5 mEq/L, with signs and symptoms of 
tremor, nausea, diarrhea, blurred vision, 
vertigo, and confusion.  When the level 
is greater than 2.5 mEq/L, toxicity is 
manifested in seizures, dysrryhthmias, 
and coma.  Treatments for lithium toxicity 
include gastric lavage, induction of 
emesis, and hemodialysis when serum 
concentration is above 2.5 mEq/L.  For 
dosing information, refer to Table 1.8,9
Valproate (Depakote®)
Formulations of valproate consists 
of valproate sodium, valproic acid, and 
divalproex sodium.  Valporate increases 
the availability of gamma-aminobutyric 
acid (GABA) and enhances or mimics 
the action of GABA.  By increasing 
GABA activity, valproates can manage 
the abnormal, persistent, and elevated 
mood in mania.  Studies have shown that 
valproate has better efficacy than lithium 
in patients with mixed episodes, many 
prior mood episodes, and rapid cycling.  
Similar efficacy is seen with olanzapine 
and haloperidol.  Valproate is used as first 
line therapy for acute mania, hypomania, 
mixed, and maintenance.  It can also be 
combined with lithium, carbamazepine, 
and antipsychotics.  After two weeks of 
initiating therapy, trough levels of acute 
manic or mixed episodes should be at 50 – 
125 mcg/mL.
Adverse effects of valproate target 
multiple organs and can be dose 
dependent.  The most common adverse 
effects are dose-related nausea, vomiting, 
diarrhea, abdominal pain, dyspepsia, and 
flatulence.  Valproate can also cause CNS 
issues, including headache, somnolence, 
dizziness, nervousness, and sedation.  
Caution must be taken in patients with 
liver disease because valproate can 
increase liver function test (LFTs) and 
precipitate hepatic failure.  Valproate can 
further cause tremor, weakness, diplopia, 
and blurred vision.  Rare but serious side 
effects are hepatic failure, pancreatitis, 
and agranulocytosis.  Valproate is 
contraindicated in pregnancy, with a black 
box warning for teratogenicity, pregnancy 
category X.
When combined with lamotrigine, 
valproate will inhibit lamotrigine’s 
metabolism and dosing adjustment is 
therefore required.  Valproate is highly 
protein bound and will displace other 
drugs readily.  Finally, it will inhibit 
CYP 450 isoenzymes 3A4, 2C9, and 
2D6.  Hematologic, hepatic, dermatologic 
and metabolic tests should be monitored 
at baseline, then every 3-6 months.  
Serum levels should also be monitored 
for toxicity, where sign and symptoms 
include somnolence, heart block, and 
coma.  Treatment of toxicity would be 
hemodialysis.  Behavior changes and 
suicide ideation should also be assessed 
periodically.  For dosing information, refer 
to Table 1.8,9
Carbamazepine (Tegretol®)
The mechanism of action of 
carbamazepine is to decrease synaptic 
transmission, decrease activity in the 
thalamus, and decrease the transport 
of sodium across cell membranes, 
and potentiating GABA receptors.  
By decreasing synaptic transmission 
via blockage of sodium across cell 
membranes, cells are less excitable and an 
abnormally elevated mood can be better 
managed.  Studies show that the efficacy 
of carbamazepine is similar to lithium, 
but less than valproate.  Carbamazepine 
is used as an alternative treatment and 
be combined with lithium, valproate, or 
antipsychotics.  There is no established 
goal serum level for carbamazepine in the 
treatment of bipolar disorder.  However, 
the target serum level of 4 – 12 mcg/
mL for seizures is often used for bipolar 
disorder.
The adverse effects of carbamazepine 
include multiple organs, with the most 
common side effects being CNS related: 
dizziness, drowsiness, headache, ataxia, 
cognitive and memory impairments, 
and rare cases of neuroleptic malignant 
syndrome (NMS).  Cardiac issues caused 
by carbamazepine include hypertension 
or hypotension, syncope, AV block, 
arrhythmias, and edema.  Gastrointestinal 
side effects are nausea, vomiting, 
diarrhea, dry mouth/throat, and anorexia.  
Impotence and polyuria can occur along 
with increase in LFTs.  Hematologic side 
effects are agranulocytosis, anemia, and 
thrombocytopenia.  Carbamazepine can 
induce symptoms of inappropriate ADH 
(SIADH), abnormal thyroid function 
test, hypocalcemia, and hyponatremia.  
Certain populations, such as Asian, Native 
American, Latin American, African-
American, and Indian are at greater 
risks of developing Stevens-Johnson 
syndrome (SJS) due to the presence of the 
HLA-B*1502 allele.
In addition to being a CYP 3A4 
inhibitor, carbamazepine also has a unique 
mechanism of being able to autoinduce 
its own metabolism.  Thus, it is important 
to adjust the dose based on patient’s 
liver function.  Since carbamazepine 
can decrease the concentration of oral 
contraceptives (OC), back up methods 
or an increase in OC dose should be 
considered.  When combined with 
clozapine, there is an increased risk of 
bone marrow suppression.  And when 
added to valproate, the concentration of 
carbamazepine will increase.  Monitor 
serum level for toxicity, which can be 
manifested in dizziness, sedation, visual 
changes, respiratory dysfunction, and 
arrhythmias.  Treatments of toxicity 
include relieving symptoms, gastric 
lavage, or hemoperfusion.  For dosing 
information, refer to Table 1.8,9
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Oxcarbazepine (Trileptal®)
The mechanism of action of 
oxcarbazepine is to decrease synaptic 
transmission by blocking sodium voltage-
gated channels, similar to carbamazepine.  
Studies have shown that oxcarbazepine 
has similar efficacy to lithium and 
haloperidol; however, these studies lack 
power.  Oxcarbazepine is used as an 
alternative treatment for bipolar either 
as monotherapy or in combination with 
other agents, after patients have failed 
carbamazepine, lithium, and valproate.  
The advantages of oxcarbazepine over 
carbamazepine include having fewer 
adverse effects, fewer drug interactions, 
and no autoinduction.  However, 
oxcarbazepine causes greater risk of 
hyponatremia, which can cause nausea, 
vomiting, confusion, and seizures.  
The most common adverse effects 
are CNS related, including dizziness, 
drowsiness, headache, ataxia, vertigo, 
fatigue, sedation.  Other side effects are 
nausea, vomiting, abdominal pain, along 
with abnormal gait and tremor, diplopia 
and nystagmus.  Cross-sensitivity to 
oxcarbazepine is seen in approximately 
25% -30% of patients who are allergic 
to carbamazepine.  Hypersensitivity 
reactions include angioedema and SJS.  
Oxcarbazepine is a CYP 3A4 inducer and 
CYP 2C19 inhibitor and will decrease 
concentrations of oral contraceptives and 
dihydropyridine calcium channel blockers. 
It is recommended to monitor serum 
levels of sodium for signs and symptoms 
of hyponatremia while patients are on 
oxcarbazepine.  For dosing information, 
refer to Table 1.8,9
Lamotrigine (Lamictal®) 
Lamotrigine, a mood stabilizer, is 
commonly used as a first-line treatment 
for patients with bipolar II disorder.  
There is a black box warning for 
serious skin rashes, which may lead 
to the SJS.  The concomitant use with 
valproate can increase this risk of rash.  
Signs of rashes should be monitored 
at baseline and every 3-6 months.  
Common adverse effects include nausea, 
vomiting, insomnia, ataxia, dizziness, 
and headache.  Carbamazepine increases 
the metabolism of lamotrigine which 
may result in subtherapeutic levels of 
lamotrigine.  There are also drug-drug 
interactions with oral contraceptives.  
The estrogen component can decrease 
the effectiveness of lamotrigine, while 
lamotrigine can decrease the effectiveness 
of oral progestin contraceptives.  Doses 
should be decreased in renal and hepatic 
impairment.  LFTs and serum creatinine 
(SCr) should be monitored regularly 
during therapy.  Anticonvulsants increase 
the risk of suicidal thoughts and behaviors, 
so patients should be monitored for 
emergence or worsening of depression or 
suicidal ideation.  For dosing information, 
refer to Table 1.8,9
Quetiapine (Seroquel®)
Quetiapine, an atypical antipsychotic, 
is used for the acute treatment of 
manic episodes associated with bipolar 
disorder, acute treatment of depressive 
episodes associated with bipolar I and 
II, and maintenance treatment of bipolar 
I disorder.  Common adverse effects 
include increase in diastolic and systolic 
blood pressure in children, somnolence, 
headache, agitation, dizziness, metabolic 
effects, dry mouth, weight gain, and 
increased appetite.  Concomitant use with 
acetylcholinesterase inhibitors should 
be avoided since severe extrapyramidal 
symptoms may be precipitated.  CYP3A4 
inducers (e.g.  progesterone, phenytoin, 
oxcarbazepine, carbamazepine, and 
phenobarbital) may decrease the 
serum level of quetiapine.  To maintain 
therapeutic benefit, quetiapine doses may 
be increased to up to 5 times when used 
with CYP3A4 inducers.  Fasting lipid 
profile (FLPs) should be monitored due 
to metabolic increases in triglyceride and 
decreased HDL levels.  Weight, blood 
pressure, worsening of depression or 
suicidal ideation should be monitored 
regularly.  For dosing information, refer to 
Table 1.8,9
Benzodiazepines
The most commonly studied and used 
benzodiazepines in bipolar disorder are 
lorazepam (Ativan®) and clonazepam 
(Klonopin®), which has beneficial effects 
in the treatment of hypomanic, mild to 
moderate manic, and mixed episodes.5  
Benzodiazepines are generally used as 
adjunctive therapy for treating insomnia, 
agitation, and anxiety in bipolar patients 
with elevated moods.  Common adverse 
effects include sedation, respiratory 
depression, hypotension, and changes in 
appetite, and therefore respiratory and 
cardiovascular status should be closely 
monitored.  Concomitant use with 
olanzapine may increase the toxicity of 
benzodiazepines.  Benzodiazepines may 
also increase the serum level of selective 
serotonin reuptake inhibitors (SSRIs), 
which increases the risk of psychomotor 
impairments.  For dosing information, 
refer to Table 1.8,9 
Selective Serotonin Reuptake Inhibitors
Examples of SSRIs are citalopram 
(Celexa®), escitalopram (Lexapro®), 
fluoxetine (Prozac®), paroxetine (Paxil®), 
and sertraline (Zoloft®).  SSRIs are 
generally used as first line antidepressants 
because of their safety in overdose 
and improved tolerability.  Common 
adverse effects include nausea, vomiting, 
diarrhea, headache, insomnia, and sexual 
dysfunction.  Citalopram can also cause 
dose-related QT prolongation and doses 
should not exceed 40 mg/day for all 
patients and should not exceed 20 mg/day 
for patients over 60 years old, have hepatic 
impairment, or are concurrently taking 
a CYP 2C19 Inhibitor (e.g. omeprazole, 
cimetidine).  Abrupt withdrawal can cause 
flu-like symptoms, light-headedness or 
dizziness, uneasiness, sleep disturbances, 
and headache.  Therefore, SSRIs should 
be tapered down when discontinuing 
treatment with the exception of fluoxetine 
due to its long half-life.  SSRIs are highly 
bound to plasma protein and co-admission 
with other highly protein-bound drugs 
(e.g.  valproate, warfarin, digoxin) may 
cause changes in serum concentrations 
of either drugs.  SSRIs have varying 
degrees of CYP 2D6 inhibition and 
may affect drugs that are metabolized 
by this isoenzyme (e.g. phenothiazine 
antipsychotics, risperidone).  Fluoxetine 
and paroxetine are strong CYP 2D6 
inhibitors while sertraline is a moderate 
CYP 2D6 inhibitor, and citalopram 
and escitalopram are weak CYP 2D6 
inhibitors.  Citalopram and escitalopram 
are metabolized by CYP 3A4 and CYP 
2C19, and concomitant use with a CYP 
3A4 inducer (e.g. carbamazepine) may 
decrease their serum levels.  Use of a 
SSRI with a MAOI is contraindicated 
due to the increased risk of hypertensive 
crisis, serotonin syndrome, and delirium.  
There is a Black Box Warning of increased 
suicidal ideation with antidepressant use 
and suicidal thoughts should be assessed 
and monitored regularly.  For dosing 
information, refer to Table 1.8,9
Bupropion (Wellbutrin®)
Bupropion works as an antidepressant 
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by inhibiting norepinephrine and 
dopamine reuptake.  Common adverse 
effects include nausea, vomiting, dry 
mouth, skin reactions, insomnia, and 
seizures.  Bupropion is metabolized 
by CYP 2B6 and has few drug-drug 
interactions.  However, concomitant 
use with carbamazepine may lower 
bupropion levels and dose adjustments 
may be required.  Contraindications with 
bupropion include concomitant use with 
a MAOI, seizure disorder, and history of 
an eating disorder.  There is a Black Box 
Warning of increased suicidal ideation 
with antidepressant use and suicidal 
thoughts should be assessed and monitored 
regularly.  For dosing information, refer to 
Table 1.8,9 
Venlafaxine (Effexor®)
Venlafaxine is a serotonin and 
norepinephrine reuptake inhibitor (SNRI) 
that is generally used as a second-line 
antidepressant.  Common adverse effects 
include significant nausea, constipation, 
dry mouth, decreased appetite, headache, 
somnolence, dizziness, insomnia, 
dose-related increase in diastolic blood 
pressure, and sexual dysfunction.  Blood 
pressure should be monitored regularly, 
and doses should be decreased in patients 
with renal and/or hepatic impairment.   
Abrupt withdrawal with SNRIs may be 
worse than with SSRIs and symptoms 
may include agitation, confusion, 
excessive sweating, hallucinations, and 
hyperreflexia.  There are minimal drug-
drug interactions but concomitant use 
with a MAOI is contraindicated.  There 
is a Black Box Warning of increased 
suicidal ideation with antidepressant use 
and suicidal thoughts should be assessed 
and monitored regularly.  For dosing 
information, refer to Table 1.8,9 
Monoamine Oxidase Inhibitors
MAOIs such as selegiline (Emsam®), 
phenelzine (Nardil®), and tranylcypromine 
(Parnate®) work by increasing 
concentrations of norepinephrine, 
serotonin, and dopamine.  They are rarely 
used as a first line drug therapy and 
are indicated for patients with atypical 
depression or patients unresponsive to 
other antidepressants.  Common adverse 
effects include orthostatic hypertension, 
sedation, stimulant, weight gain, and 
sexual dysfunction.  Hypertensive 
crisis may occur when taken with 
food containing tyramine and other 
antidepressants.  Overdose can occur 
and symptoms may include irritability, 
hyperactivity, anxiety, tachycardia, 
drowsiness, and hallucinations.  There 
are many drug-drug interactions 
and contraindications to MAOIs 
include concomitant use with other 
antidepressants, pheochromocytoma, 
congestive heart failure, hepatic 
impairment, renal impairment, 
cerebrovascular disorders, cardiovascular 
disease, hypertension, and history of 
headache.  There is a Black Box Warning 
of increased suicidal ideation with 
antidepressant use and suicidal thoughts 
should be assessed and monitored 
regularly.  For dosing information, refer to 
Table 1.8,9
Olanzapine/ fluoxetine (Symbyax®) 
This combination agent contains 
olanzapine, a SGA that inhibits 
serotonin, dopamine, histamine, and 
alpha1-adrenergic reuptake, and the 
SSRI fluoxetine.   Due to the synergistic 
increase in serotonin, norepinephrine, 
and dopamine, there is an enhanced 
antidepressant effect for this drug 
combination.  Olanzapine/fluoxetine is 
commonly used for depressive episodes 
associated with bipolar I disorder and 
treatment-resistant depression, which 
is defined as being unresponsive to two 
trials of different antidepressants in 
the current episode.  Common adverse 
reactions to this combination agent include 
somnolence, fatigue, hyperprolactinemia, 
weight gain, increased appetite, and 
dry mouth.  There are many drug-drug 
interactions associated with olanzapine/
fluoxetine and concomitant use with 
other SSRIs, antipsychotics, and lithium 
may lead to serotonin syndrome/toxicity.   
Concomitant use with a MAOI should be 
avoided.  Doses should be decreased in 
hepatic impaired and hypotensive patients, 
and LFTs and blood pressure should be 
monitored regularly in these patients.  For 
dosing information, refer to Table 1.8,9
SPecIAl POPulATIONS
Women and Pregnancy
Due to higher risks of birth 
malformations associated with 
medications used to treat bipolar 
disorder, all female patients of 
childbearing age are encouraged to 
practice effective contraceptive methods 
while on pharmacological therapy.5  
Oral contraceptives should be avoided 
in patients taking carbamazepine, 
oxcarbazepine, and topiramate because 
these medications increase the metabolism 
of oral contraceptives, thus decreasing 
their effectiveness.  Effective backup 
contraceptive practices, such as condoms 
or intrauterine devices, are recommended 
for birth control in these patients.   
When a patient is pregnant, the risks and 
benefits of continuing versus discontinuing 
medications for bipolar disorder should be 
evaluated carefully.  Should the decision 
be made to continue pharmacotherapy, 
clinicians and pharmacists should choose 
drugs with fewer known teratogenic 
effects and when possible, the lowest 
effective dose should be used.  Congenital 
malformations have been documented 
with first-trimester exposure to lithium, 
valproate, and carbamazepine.  A common 
neonatal complication associated with 
lithium use near labor is the “floppy 
baby” syndrome, which is characterized 
by cyanosis and hypotonicity.  The use 
of carbamazepine and valproate sodium 
during the first trimester has been 
associated with neural tube defects.10  
Benign risks have been documented 
with SSRIs use during pregnancy, with 
fluoxetine and citalopram having the 
strongest safety data.  Similarly, past 
studies have demonstrated no association 
between lorazepam and clonazepam with 
birth defects.  However, diazepam remains 
controversial due to earlier reports of 
increased risks of oral cleft malformations 
during the first trimester.10  Antipsychotic 
medications may be added to the bipolar 
regimen to treat psychotic features.  High-
potency antipsychotic agents are preferred 
due to their decreased anticholinergic, 
antihistaminergic, and hypotensive 
effects.5  Use of high-potency agents 
near term, however, has demonstrated 
short-lived extrapyramidal side effects in 
neonates.   Haloperidol is recommended 
as the first line therapy because it is not 
associated with congenital anomalies.5 
Prenatal monitoring is recommended 
for all females who choose to remain 
on lithium, valproate, or carbamazepine 
during their pregnancy.12  At the 
20th week of gestation, a maternal 
serum of α-fetoprotein screening for 
neural tube defects is recommended 
with amniocentesis.  Ultrasound 
examination at 16-18 weeks gestation 
is also recommended to detect cardiac 
abnormalities.  Close monitoring of the 
serum drug levels should be continued 
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throughout the pregnancy due to changes 
in hepatic metabolism, renal excretion, 
and fluid volumes.
Postpartum and Breast-feeding
During the postpartum period, females 
are more likely to relapse into mania, 
depression, or psychosis.  Women with 
previous postpartum episodes have the 
highest risk to have another affective 
episode after subsequent pregnancies.  
Therefore, prophylactic medications such 
as lithium or valproate are recommended 
in women with bipolar disorder to prevent 
postpartum mood episodes.5  Pharmacists 
should also counsel women on the 
importance of maintaining a normal sleep 
pattern to avoid precipitating episodes of 
mania.
Although all medications used in the 
treatment of bipolar disorder are secreted 
in breast milk at different degrees, the 
risks of breastfeeding must be weighed 
against the benefits in this patient 
population.  Lithium is not recommended 
during lactation, because it is secreted 
in breast milk at 40% of maternal serum 
concentration.5  Lamotrigine level 
is secreted at 25% of maternal level, 
but no recommendations are made 
concerning its use in breastfeeding.5  
Other antipsychotics, antidepressants, and 
benzodiazepines are found in measurable 
levels in breast milk and have the potential 
to affect the infant’s central nervous 
system.
Pharmacist Role/conclusion 
Bipolar disorder can be effectively 
managed with the help of pharmacists, 
physicians, and psychiatrists.  As clinical 
pharmacists, obtaining an accurate and 
complete medication history is critical to 
identifying potential medication-related 
causes of mood episodes.  Pharmacists can 
also help to assess the number of manic 
and depressive episodes throughout the 
course of therapy to optimize the patient’s 
medication therapy.  Patient education 
is an important component to successful 
therapy management.  By educating the 
patient about the disease state and the 
drug therapy, patients are empowered 
to take charge of their own health and 
are therefore more likely to maintain 
medication adherence.  In addition, 
performing long-term monitoring as part 
of medication therapy management can 
increase patient adherence and reduce 
future hospitalizations.  
It is crucial that the patients and 
their family members understand the 
importance of medication adherence 
for safety and efficacy purposes.  For 
instance, patients may not be aware that 
abrupt discontinuation of an SSRI may 
lead to withdrawal syndromes or that 
non-adherence can worsen their mood 
episodes.  It is especially essential to 
educate special patient populations, such 
as patients with pregnancy and lactation 
concerns due to the high teratogenic risk.   
It is also important to educate the patients 
and their family members to identify 
behavioral changes and early signs of 
suicidal ideation as serious side effects of 
the medication.  Overall, pharmacists can 
have a significant role in the management 
and well-being of their bipolar patients 
by helping them to monitor and provide 
education about their disease state.
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Table 1: Drug Dosing 
 
Drug Initial Dose (mg/day) Usual Dose (mg/day) 
Lithium  900 in 3-4 divided doses 0.5-1.2 mEq/L (serum 
level) 
Valproate 750 in 3 divided doses 60 mg/kg 
Carbamazepine 400 in 2 divided doses 800-1000 
Oxcarbazepine 600 1200 
Lamotrigine 25-50 100-400 
Olanzapine/Fluoxetine 6/25 6-12(O)/25-50(F) 
Quetiapine  50 300-800 
Citalopram  20 20-40 
Escitalopram  10 10-20 
Fluoxetine 20 20-60 
Paroxetine 20 20-60 
Sertraline  50 50-200 
Buproprion 150 150-300 
Venlafaxine  37.5-75 75-375 
Selegiline 6 6-12 
Phenelzine 45 in 3 divided doses 45-90 
Tranylcypromine  10 30-60 
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